Tomita, Naohiro http://orcid.org/0000-0002-0963-1533
Ishida, Hideyuki
Tanakaya, Kohji
Yamaguchi, Tatsuro
Kumamoto, Kensuke
Tanaka, Toshiaki
Hinoi, Takao
Miyakura, Yasuyuki
Hasegawa, Hirotoshi
Takayama, Tetsuji
Ishikawa, Hideki
Nakajima, Takeshi
Chino, Akiko
Shimodaira, Hideki
Hirasawa, Akira
Nakayama, Yoshiko
Sekine, Shigeki
Tamura, Kazuo
Akagi, Kiwamu
Kawasaki, Yuko
Kobayashi, Hirotoshi
Arai, Masami
Itabashi, Michio
Hashiguchi, Yojiro
Sugihara, Kenichi
Tomita, Naohiro
Ishida, Hideyuki
Tanakaya, Koji
Yamaguchi, Tatsuro
Kumamoto, Kensuke
Tanaka, Toshiaki
Hinoi, Takao
Miyakura, Yasuyuki
Hasegawa, Hirotoshi
Ishikawa, Hideki
Nakajima, Takeshi
Chino, Akiko
Sekine, Shigeki
Tamura, Kazuo
Akagi, Kiwamu
Kobayashi, Hirotoshi
Arai, Masami
Itabashi, Michio
Hashiguchi, Yojiro
Sugihara, Kenichi
,
Funding for this research was provided by:
JSCCR
Article History
Received: 23 December 2020
Accepted: 10 January 2021
First Online: 29 June 2021
Declaration
:
: All members with the exception of the discussion chair (committee chair) voted in all CQs. None of the committee members reported on economic COIs, determined according to the rules of the JSCCR. Also, none of the commissioners had academic COIs for CQs. Therefore, all of the committee members except the discussion chair voted in all CQs. Conflict of interest statements according to rules of the International Journal of Clinical Oncology was as follows. Naohiro Tomita received a research grant from Taiho pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., and Sysmex Co.; Hideyuki Ishida received a research grant from Chugai Pharmaceutical Co., Ltd.,Eli Lilly Japan K.K. and Taiho pharmaceutical Co., Ltd.; Kiwamu Akagi received honoraria from MSD Co., Ltd., Taiho pharmaceutical Co., Ltd. and Takeda Pharmaceutical Co., Ltd., received a research grant from Ono Pharmaceutical Co. Ltd. and FALCO Biosystems Co., Ltd.; Michio Itabashi received a research grant from Taiho pharmaceutical Co., Ltd., Pfizer Japan, Inc., Astellas Pharma, Inc., Chugai Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Co., Ltd. Other authors declare that they have no conflict of interest.